Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07770074 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT07770074 · ClinicalTrials.gov record · last posted 2026-08-18

A Real-World Study of Second-line Therapies Among Radioiodine-refractory Differentiated Thyroid Cancer (RAI-R DTC) Patients

Name: A Real-World Study of Second-line Therapies Among Radioiodine-refractory Differentiated Thyroid Cancer (RAI-R DTC) Patients — clinical trial record (NCT07770074)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusNot Yet Recruiting

PhaseNot specified

SponsorNovartis Pharmaceuticals

Started2026-10-08

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

This study aims to assess patient characteristics and treatment patterns of second-line systematic therapies, including BRAF V600E mutation-guided dabrafenib plus trametinib (D+T) and MKIs, among Chinese adult patients with RAI-R DTC. This is a non-interventional study using secondary data derived from a real-world Electronic Health Record (rEHR) database in China.

Trial Details

NCT Number	NCT07770074
Lead Sponsor	Novartis Pharmaceuticals
Conditions	Radioiodine-refractory Differentiated Thyroid Cancer
Enrollment	200 participants
Start Date	2026-10-08
Primary Completion	2026-10-31 (estimated)
Study Completion	2026-10-31 (estimated)
Updated on ClinicalTrials.gov	2026-08-18